psalexa

Herpes Simplex Virus (HSV) Infections Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

  • Published: May 2017
  • Report Code: LS10973
  • Available Format: PDF
  • Pages: 77

Note: This report can also be updated as of date and delivered within 1-2 working days of purchase confirmation

Disease Overview

Herpes is an infection caused by a virus known as, herpes simplex virus. It is estimated, that around 3.7 billion people under the age of 50 years are suffering with the herpes simplex virus infection, globally. The disease is categorized into two types: HSV1 and HSV2. HSV1, also known as oral herpes can lead to sores on the mouth and around the lips, HSV2 causes genital herpes. A person can get infected with HSV1 by sharing lip balm, kissing and eating from the same utensils. HSV2 spreads through sexual contact with a person, already suffering from HSV2.

Both HSV1 and HSV2 belong to the herpes virus family and their genome consists double stranded DNA within an icosahedral nucleocapsid. Outside this capsid, the virus is covered by a lipid membrane layer. The lipid membrane layer can be affected by environmental factors such as detergents, solvents and heat. These viruses generally do not remain viable in the environment; direct inoculation is thus required for the infection to be transmitted. Some of the risk factors of HSV2 virus include sex with multiple partners, sex at a young age, a weak immunity and sexually transmitted infection. Some of the symptoms associated with Herpes infection are blistering sores, itching, and pain during urination, tiredness, headache, loss of appetite etc. Herpes simplex virus can be easily diagnosed by physical appearance and also by performing certain lab tests which include a DNA or a PCR test.

Pipeline Analysis

As of May 2017, the herpes simplex virus infection therapeutics pipeline comprised of approximately 20 drug candidates in different stages of development.

 

NUMBER OF HERPES SIMPLEX VIRUS INFECTIONS THERAPEUTICS UNDER DEVELOPMENT (2017)

Herpes Simplex Virus Infections Therapeutics Pipeline Analysis

Competitive Landscape

Some of the key players developing drugs for Herpes virus simplex infections include Vical, Inc., Maruho Co., Ltd., Sanofi Pasteur and others.

Scope for Customization

P&S Intelligence offers customization as per specific business requirements of clients. Illustrative customization within the scope of this report includes:

  • Market Forecast – Market analysis and forecast for the drug candidates in the latest stage of development
  • Company Profiles – Wider company coverage in terms of detailed analysis or additional company profiles
Place An Order
USD 1500 USD 1800 USD 2200
Customized Report Solution

Get a bespoke market intelligence solution

 
We are committed to ensuring the highest level of client satisfaction
Quality Acknowledgement
Quality Acknowledgement

Our dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you

Unmatched Standards
Unmatched Standards

Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights

Reach Us
Reach Us Whenever You Need Us

With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required

Data Security
Complete Data Security

We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws